Nonpathogenic, naturally occurring human enterovirus strains that possess a high potency for killing cancer cells — in vitro and in vivo — with decades of human safety data behind every candidate.
Conventional chemotherapy and targeted agents carry severe adverse effects. Immunotherapies help only a subset of patients. Engineered oncolytic viruses have shown modest response rates in clinical use. Patients with advanced, hard-to-treat cancers deserve something different.
Our platform combines a library of bioselected natural viruses with a sequential and/or simultaneous dosing protocol and an optional dendritic cell delivery carrier — each approach protected by issued or pending patents. Sequential use of several different viruses overcomes the effects of neutralizing antibodies and extends treatment durations. Combinations of two or three viruses yield a substantially improved therapeutic response, allowing for faster and more aggressive treatment options.
A collection of nearly 30 non-pathogenic oncolytic viruses bioselected for their ability to replicate selectively inside cancer cells.
Administered intravenously rather than injected into tumors directly — so metastatic and hard-to-reach disease is accessible.
Different viruses delivered sequentially — or in combination — out-pacing the immune system's ability to clear any single agent and hitting tumors through multiple mechanisms for a stronger therapeutic response.
An optional next-generation delivery platform uses dendritic cells as carriers — delaying the antibody response to the virus hidden inside, and following the gradient of cytokines secreted by the tumor to efficiently escort the payload to its target.
Comprehensive intellectual property protects and accelerates the development plan. US and international patents issued, with subsequent applications pending and recent allowances received.
Sator's companion diagnostic predicts a patient's response to a given virus strain — without direct testing of cancer cells for virus sensitivity. Identifying responders up front avoids treating patients who will not benefit, and addresses the central problem of current oncolytic virotherapy: typical response rates of less than 10–20%.
Predicts response to a specific oncolytic virus before treatment, identifying the patients most likely to benefit.
Spares patients from treatment with a virus their tumor will not respond to — conserving time, resources, and patient health for therapies that work.
Designed to overcome the historic 10–20% response rate ceiling of single-agent oncolytic virotherapy by routing each patient to the right virus.
Avoids the need for live cancer-cell sensitivity testing — faster, more scalable, and compatible with standard clinical pathology workflows.
Mesothelioma is our lead indication. Additional research programs span hard-to-treat solid tumors where current standards of care are limited or ineffective.
The oncolytic virus field is poised for a breakthrough decade, with billions in strategic deal activity and a clear regulatory path for differentiated platforms. Sator's combination of naturally-occurring viruses, systemic delivery, and sequential dosing is purpose-built for the indications where current OV candidates fall short.
Disclosed deal value across oncolytic virus partnerships and acquisitions has exceeded four billion dollars, signaling deep strategic commitment from large biopharma.
Straightforward CMC and clinical development paths. Sator's lead programs are eligible for US FDA Orphan Drug Designation and biologic exclusivity — providing market exclusivity and patent-life extension on top of an already comprehensive IP estate.
Approved and late-stage OVs are engineered and injected into tumors directly. Sator's library is naturally-occurring, administered systemically, and delivered in sequential combinations — a different therapeutic profile for a different patient population.
A record of Sator's corporate, patent, and platform milestones. Detailed technical and business updates are available through the investor portal.
Sator's Chief Technology Officer outlined the company's patented approach to synonymous codon optimization and its dendritic cell delivery carrier in a two-part published interview with manufacturing partner Batavia Biosciences, describing how the platform aims to overcome neutralizing antibody responses that have limited conventional oncolytic virus response rates.
Company leadership presented Sator's natural-virus oncology platform to the Rotary Club of Cleveland, outlining the company's patent-protected platform and its broader mission of bringing safer cancer treatments to patients with hard-to-treat disease.
U.S. Patent Application Serial No. 16/868,691 — “Delivery of Oncolytic Viruses Using Dendritic Cells” — received a Notice of Allowance from the U.S. Patent and Trademark Office on February 5, 2026. The allowed claims cover Sator's dendritic-cell-mediated systemic delivery platform, completing the company's patent coverage of its core delivery strategy.
U.S. Patent Application Serial No. 17/543,333 — a continuation in the “Optimized Oncolytic Viruses and Uses Thereof” family — received a Notice of Allowance on September 12, 2025. The allowed claims cover methods of treating animal cancers with Sator's oncolytic viruses, opening a parallel veterinary oncology application of the platform.
U.S. Patent No. 12,357,664 — “Optimized Oncolytic Viruses and Uses Thereof” — was issued by the USPTO on July 15, 2025. The patent describes methods of creating next-generation codon-optimized synthetic viruses targeting cancerous tumors with superior efficiency, expanding the company's IP estate beyond the naturally-occurring library.
U.S. Patent No. 11,253,558 — “Optimized Oncolytic Viruses and Uses Thereof” — was issued by the USPTO on February 22, 2022. The patent covers Sator's signature combinatorial-use approach to oncolytic virotherapy, including both sequential and simultaneous administration of multiple viruses to overcome neutralizing antibody responses.
Note on forward-looking content. This newsroom summarizes publicly verifiable events in Sator's corporate and intellectual-property history. Patent application publication does not constitute a grant of patent rights, and Notices of Allowance precede the formal issuance of patent claims. Please see the disclaimers at the bottom of this page.
Whether you're a patient advocate, a scientific collaborator, or an investor tracking the oncolytic virus space, there's a path into Sator that fits. Pick the one that matches your interest.
Already have investor portal credentials? Sign in →
Capital is being deployed toward IND-enabling studies and formal trials for the lead mesothelioma program. A complete data room — clinical precedent, patent portfolio, preclinical efficacy, and commercial strategy — is available to qualified investors under NDA. Access requires a brief qualification step.
Request investor access Pharma, partners, patients & pressStrategic partnerships, scientific collaborations, patient or caregiver questions, press inquiries, students. We read every message and route it to the right person at Sator. We do our best to respond, even if we can’t always share everything publicly.
Send a messageSator's naturally-occurring oncolytic viruses, sequential dosing platform, and dendritic cell delivery system are advancing toward formal clinical development. For patients, for caregivers, and for the scientific partners who will help bring this work to the clinic.